TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03152747

Intervention type: DEVICE
Intervention: ultrasound, b-scan
Description: Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.

Intervention type: DEVICE
Intervention: ultrasound, b-scan
Description: Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
Study: NCT02532777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide(CTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil(MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide(LEF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor(ACEI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor(ACEI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor(ACEI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study: NCT04484922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: continuous infusion of dexmedetomidine during the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: continuous infusion of normal saline during the surgery
Study: NCT00002571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: 5u/m2 IV Q21days x 6 cycles
Study: NCT04952324

Intervention type: OTHER
Intervention: Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP
Description: Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP

Intervention type: OTHER
Intervention: Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP
Description: Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
Study: NCT00002571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5ug/kg SC, Days 9-20, Q 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 490 mg/m2 IV Q 21 days x 6 cycles
Study: NCT01808690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00002571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 225 mg/m2 IV Q 21 days x 6 cycles
Study: NCT02516618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Study: NCT00002571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 19 mg/m2 IV Q 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 90 mg/m2 IV Q 21 days x 6 cycles
Study: NCT02516618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02644460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Study: NCT00002571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 90 mg/m2 IV, Q 21 days x 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/m2 po QD x 14days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: 1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m2 IV Q 21 Days x 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal cytarabine
Description: If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy.
Study: NCT04108169

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion surgery
Description: CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
Study: NCT01589003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycaemic index growing up milk
Description: Low Glycaemic index growing up milk

Intervention type: OTHER
Group type: OTHER
Intervention: High GI growing up milk
Description: High glycaemic index growing up milk
Study: NCT02245191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: 5mg after Spinal Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 100mcg after Spinal Anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaraminol
Description: 200mcg Metaraminol after Spinal Anesthesia
Study: NCT01109459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric blood pressure screening
Description: Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric vision screening
Description: Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
Study: NCT02134574

Intervention type: BIOLOGICAL
Intervention: hematologic malignancy
Description: hematologic malignancy with a sampling of blood
Study: NCT01892423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Moisturizing Lotion Daily Advance
Study: NCT02277821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stendo pulsating suit System
Description: The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
Study: NCT02987595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain rye, high lignan
Description: Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain rye, high lignan
Description: Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat, low lignan
Description: Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat, low lignan
Description: Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
Study: NCT03555721

Intervention type: OTHER
Intervention: Oral examination with incandescent light
Description: Suspicious oral lesions will be identified by oral examination with incandescent light.

Intervention type: OTHER
Intervention: Oral examination with OralID
Description: OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy
Description: Tissue will be collected to identify pre-cancerous or cancerous cells

Intervention type: DIAGNOSTIC_TEST
Intervention: CytID
Description: CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.

Intervention type: DIAGNOSTIC_TEST
Intervention: hpvID
Description: hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
Study: NCT02638662

Intervention type: OTHER
Intervention: Observational
Description: Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
Study: NCT04303494

Intervention type: BIOLOGICAL
Intervention: immunisation
Description: combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination

Intervention type: BIOLOGICAL
Intervention: immunisation
Description: combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination

Intervention type: BIOLOGICAL
Intervention: immunisation
Description: combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
Study: NCT03914144

Intervention type: OTHER
Intervention: Catheter insertion
Description: A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.

Intervention type: OTHER
Intervention: Catheter insertion
Description: A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.

Intervention type: OTHER
Intervention: Catheter insertion
Description: A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.

Intervention type: OTHER
Intervention: Catheter insertion
Description: A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
Study: NCT03197961

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine
Description: At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPA
Description: After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
Study: NCT03251183

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
Study: NCT02638662

Intervention type: OTHER
Intervention: Observational
Description: Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire

Intervention type: OTHER
Intervention: Observational
Description: Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
Study: NCT05884060

Intervention type: OTHER
Intervention: No intervention
Description: No interventions

Intervention type: OTHER
Intervention: No intervention
Description: No interventions
Study: NCT03251183

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Cardiovascular magnetic resonance (CMR)
Description: Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
Study: NCT01240174

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Demonstration of near zero antibiotic prescribing for patients with acute bronchitis
Description: A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
Study: NCT00675740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: tablets 4 mg daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: stationary bike 5-6 times a week

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: control without intervention
Study: NCT04213885

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL 330 Platinum device/Riboflavin
Description: 30mW, 5 sec, 5 sec off, 10 minutes of illumination
Study: NCT03251183

Intervention type: DIAGNOSTIC_TEST
Intervention: Left ventricular (LV) biopsy
Description: A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status.
Study: NCT02754323

Intervention type: DEVICE
Group type: OTHER
Intervention: Apparatus CODESNA
Description: The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
Study: NCT04525742

Intervention type: OTHER
Group type: OTHER
Intervention: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic
Description: It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
Study: NCT03205514

Intervention type: DIAGNOSTIC_TEST
Intervention: NSTE-ACS with intermediate stenosis and negative FFR
Description: Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
Study: NCT01625429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
Study: NCT00989651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT03467594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: • Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
Study: NCT03115879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip mobilization
Description: High velocity low amplitude hip mobilization of the experimental group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hip manipulation simulation
Description: Hip manipulation simulation
Study: NCT01580462

Intervention type: OTHER
Intervention: Observational study
Description: Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded.
Study: NCT01709643

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High fat breakfast
Description: The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands).
Study: NCT00989651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP
Study: NCT01809314

Intervention type: DRUG
Intervention: Epoetin beta
Description: Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
Study: NCT04418427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6E11 vg/eye of ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept